Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

What this Trial Is About

Researchers are evaluating the addition of dupilumab, a biological treatment, to standard intranasal corticosteroids for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), focusing on a mostly ethnical and racial minority population. This study aims to confirm dupilumab's effectiveness in these underrepresented groups, establish a biomarker indicating therapeutic response, and assess its impact on asthma symptoms and lung function in those with comorbid asthma. Participants will receive dupilumab according to FDA-approved use alongside their standard care. The study includes a screening visit, a baseline visit for treatment administration, and follow-ups at 2 weeks, 16 weeks, 36 weeks, and 52 weeks to monitor progress and effects. These visits will track changes in symptoms and biological markers over time. During the study, participants will complete evaluations such as the Sinonasal Outcome Test (SNOT-22), the University of Pennsylvania Smell Identification Test (UPSIT), and nasal peak flow measurements at multiple time points. Researchers will also monitor urinary leukotriene E4, blood eosinophil counts, and immunoglobulin E levels to understand the biological effects of dupilumab. The total participation lasts about one year with scheduled assessments to observe treatment impact and safety.

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis